Morningside Venture Investments Ltd sold $3.6M of AMLX
owner at Amylyx Pharmaceuticals, Inc.. 100,000 shares at an average of $35.78, traded Feb 22, 2023, filed Feb 24, 2023.
Score components
- +12Role10% owner
- +25Trade size$3.6M at market
- 0Share of holdings soldSold 1.3% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000899243-23-006123, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 22, 2023 | SOpen-market sale Common Stock | -39,916 | $35.91 | $1.4M | 7,640,682 | Feb 24, 2023 |
| Feb 22, 2023 | SOpen-market sale Common Stock | -10,084 | $36.34 | $366k | 7,630,598 | Feb 24, 2023 |
| Feb 23, 2023 | SOpen-market sale Common Stock | -48,889 | $35.55 | $1.7M | 7,581,709 | Feb 24, 2023 |
| Feb 23, 2023 | SOpen-market sale Common Stock | -1,111 | $36.24 | $40k | 7,580,598 | Feb 24, 2023 |
Related signals
Other insiders at Amylyx Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 18Weak | Amylyx Pharmaceuticals, Inc. | George M Milne Jr director | $831k 30,000 shares | -4% | |
| 65Notable | Amylyx Pharmaceuticals, Inc. | Justin B. Klee Co-Chief Executive Officer | $980k 30,464 shares | -1% | |
| 65Notable | Amylyx Pharmaceuticals, Inc. | Joshua B Cohen Co-Chief Executive Officer | $981k 30,464 shares | -1% | |
| 44Moderate | Amylyx Pharmaceuticals, Inc. | Gina Mazzariello Chief Legal Officer | $310k 9,536 shares | -5% | |
| 52Moderate | Amylyx Pharmaceuticals, Inc. | James M Frates Chief Financial Officer | $350k 10,810 shares | -4% | |
| 44Moderate | Amylyx Pharmaceuticals, Inc. | Camille L Bedrosian Chief Medical Officer | $325k 10,028 shares | -3% | |
| 19Weak | Amylyx Pharmaceuticals, Inc. | Gina Mazzariello Chief Legal Officer | $539k 30,000 shares | -14% | |
| 29Weak | AMLXbuy Amylyx Pharmaceuticals, Inc. | Karen Firestone director | $51k 3,800 shares | +6% | |
| 40Moderate | Amylyx Pharmaceuticals, Inc. | Gina Mazzariello Chief Legal Officer | $99k 6,844 shares | -5% | |
| 47Moderate | Amylyx Pharmaceuticals, Inc. | James M Frates Chief Financial Officer | $115k 7,909 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.